Gunagratinib (ICP-192) is a pan-FGFR (fibroblast growth factor receptors) inhibitor with IC50 of 1.4, 1.5, 2.4 and 3.5 nM for FGFR1-4, respectively. It has the potential to treat advanced solid tumors.

Gunagratinib (ICP-192) is a pan-FGFR (fibroblast growth factor receptors) inhibitor with IC50 of 1.4, 1.5, 2.4 and 3.5 nM for FGFR1-4, respectively. It has the potential to treat advanced solid tumors.

Gunagratinib (ICP-192) is a pan-FGFR (fibroblast growth factor receptors) inhibitor with IC50 of 1.4, 1.5, 2.4 and 3.5 nM for FGFR1-4, respectively. It has the potential to treat advanced solid tumors.

Gunagratinib (ICP-192) is a pan-FGFR (fibroblast growth factor receptors) inhibitor with IC50 of 1.4, 1.5, 2.4 and 3.5 nM for FGFR1-4, respectively. It has the potential to treat advanced solid tumors.

KJ Pyr 9 is an inhibitor of MYC with a Kd of 6.5 nM in in vitro assay.

SR144528 is a potent and selective CB2 receptor antagonist with a Ki of 0.6 nM.

MSC-4381 (MCT4-IN-1) is an orally active, selective inhibitor of monocarboxylate transporter 4 (MCT4) with an IC50 of 77 nM and a Ki of 11 nM. It has the potential to inhibit lactate efflux and promote intracellular lactate accumulation in MCT4-expressing cell lines.

MSC-4381 (MCT4-IN-1) is an orally active, selective inhibitor of monocarboxylate transporter 4 (MCT4) with an IC50 of 77 nM and a Ki of 11 nM. It has the potential to inhibit lactate efflux and promote intracellular lactate accumulation in MCT4-expressing cell lines.

MSC-4381 (MCT4-IN-1) is an orally active, selective inhibitor of monocarboxylate transporter 4 (MCT4) with an IC50 of 77 nM and a Ki of 11 nM. It has the potential to inhibit lactate efflux and promote intracellular lactate accumulation in MCT4-expressing cell lines.

MSC-4381 (MCT4-IN-1) is an orally active, selective inhibitor of monocarboxylate transporter 4 (MCT4) with an IC50 of 77 nM and a Ki of 11 nM. It has the potential to inhibit lactate efflux and promote intracellular lactate accumulation in MCT4-expressing cell lines.